Traditional MedicareCoverageMedium impact
MolDX: Molecular Testing for Solid Organ Allograft Rejection
Medicare/CMS - LCD·Transplant Surgery, Nephrology, Internal Medicine·Local Coverage Determination
Effective date
Aug 30, 2026
We identified it
Jul 16, 2026
Summary
WPS Insurance Corporation (MAC Part A/B for Traditional Medicare) is implementing a new Local Coverage Determination for molecular testing related to solid organ allograft rejection. This policy establishes coverage parameters, medical necessity requirements, and billing guidelines for MolDX testing in transplant patients. The policy becomes effective August 30, 2026, requiring billing teams to understand coverage criteria and update claim submission processes to align with the new LCD.
Action Required
By August 29, 2026: (1) Billing team must obtain and review the complete LCD L40249 policy text from the CMS Medicare Coverage Database to identify all covered CPT/HCPCS codes, medical necessity requirements, and any prior authorization mandates. (2) Update billing software and claim submission templates to incorporate any new coding requirements or coverage restrictions for molecular allograft rejection testing. (3) Alert transplant surgery and nephrology providers about coverage criteria and documentation requirements to ensure claims include proper medical justification. (4) Train billing staff on any new prior authorization procedures or claim denial scenarios outlined in the policy. (5) Implement a system to flag claims for allograft rejection testing for review against the new LCD requirements before submission to WPS MAC. Failure to comply may result in claim denials or payment recoupment.